ITALY – PinCell, a Milan, Italy–based biotechnology company developing novel therapies for rare dermatological diseases, recently raised €1.65m in seed financing.
The round was led by Sofinnova Partners. The company intends to use the funds to continue to expand its development efforts. Founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Dr. Alessandra Marconi, PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe skin diseases with high unmet medical need. The company has also appointed Gabriella Camboni, M.D., as Chief Executive Officer and Member of the Board of Directors, and Luigi Costa as Chairman of the Board. Paola Pozzi, Partner at Sofinnova Partners, also joined PinCell’s Board. 07/05/2020
